TaiMed Biologics announced on the 24th that it has signed an exclusive commercialization and regulatory agreement with Slim Pharmaceuticals for the distribution of its breakthrough HIV drug, Trogarzo, in Sri Lanka.
TaiMed CEO, Dr. Chin-Ming Chang, emphasized that the company has been actively expanding Trogarzo’s presence beyond the U.S. market. Over the past year, the drug’s commercial footprint has extended to the Middle East, North Africa, Hong Kong, Macau, and Taiwan. The latest partnership with Slim Pharmaceuticals marks a significant milestone in TaiMed’s global expansion strategy.
Trogarzo is the world’s first FDA-approved long-acting monoclonal antibody for the treatment of HIV. It is specifically designed for patients with multidrug-resistant (MDR) HIV-1 who have experienced treatment failure with conventional antiretroviral therapies. The drug is administered biweekly via intravenous infusion or intravenous push, offering a novel treatment option for those with limited therapeutic alternatives. Following its U.S. approval, TaiMed is actively working to secure market access for Trogarzo in additional countries and regions.
Founded in 2011 and headquartered in Sri Lanka, Slim Pharmaceuticals (Pvt) Ltd is a leading distributor of high-quality pharmaceuticals. The company collaborates with global pharmaceutical firms to provide innovative and reliable medical solutions across Sri Lanka’s public and private healthcare sectors. Its extensive nationwide distribution network ensures broad access to advanced therapies for patients in need.
TaiMed Biologics continues to experience robust financial growth. In 2023, the company reported revenue of NT$610 million, reflecting a 24.1% year-over-year increase. In January 2024 alone, revenue reached NT$49 million, marking a 13.6% annual growth. With strategic partnerships such as the agreement with Slim Pharmaceuticals, TaiMed is poised to further strengthen its global market position and enhance access to life-saving HIV treatments.
